N/A N=500 Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia
Gram-negative Bacteremia
Primary: Hours to First Antibiotic Modification — 24.7; 19.0 hours — p=0.013
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1,379 GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
Sepsis
Primary: Percentage of Participants With 28-Day All Cause Mortality — 26.9; 25.8; 31.3 Percentage of participants — p=0.329
N/A N=262 Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Phase 3 N=333 Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant
Phase 3 N=207 Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Acinetobacter Baumannii-calcoaceticus Complex · Hospital-acquired Bacterial Pneumonia · Ventilator-associated Bacterial Pneumonia
Primary: Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population — 12; 20 Participants
N/A N=500 Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Bloodstream Infection · Sepsis Bacterial · MRSA Bacteremia
Primary: Time to Last Dose of Intravenous Vancomycin — 19.0; 12.5 time in hours
Phase 3 N=68 Group B Streptococcus Response After Probiotic Exposure
Group B Strep Infection
Primary: GBS Culture Result (Positive Versus Negative) — 3; 6; 18; 19 Participants
N/A N=700 Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients
Urinary Tract Infection · Infection Due to ESBL Bacteria · Environmental Contamination of ESBL
Primary: Treatment Failure — 23; 101 Treatment success
Phase 3 N=152 Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Healthcare-associated Pneumonia (HCAP) · Bloodstream Infections (BSI) · Hospital Acquired Pneumonia (HAP)
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) in Participants With HAP/VAP/HCAP or BSI/Sepsis — 50.0; 52.6; 43.5; 42.9 percentage of participants
Phase 2 N=52 Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
Gonorrhoea
Primary: Rectal Mucosal IgG Concentrations (Geometric Mean Titers [GMT]) Against N. Gonorrhoeae Outer Membrane Vesicle (OMV) Antigen Ng1291 — 0.07; 0.072; 0.089; 0.097 titer
Phase 1 N=60 Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
Phase 2 N=667 Prevention of GBS Colonization Via Immunity
Beta Haemolytic Streptococcal Infection
Primary: The Time to First Vaginal Swab That is Type III GBS Culture Positive, With All Previous Cultures Negative for Type III GBS, Not Just the Immediately Preceding Culture…
Phase 3 N=32 Aztreonam for Pharyngeal Gonorrhea
Gonorrhea of Pharynx · Gonorrhea
Primary: Treatment Efficacy of Pharyngeal Gonorrhea as Defined as the Proportion of Study Participants With Positive Pharyngeal Gonorrhea Culture at of Enrollment Whose Test of…
Phase 1 N=16 Inhaled Tobramycin in BPD
Bronchopulmonary Dysplasia
Primary: Elevated Serum Tobramycin Trough or Creatinine or Severe Adverse Event — 0; 0; 0; 1 Participants
N/A N=983 Probiotics and Infections in Conscripts in Military Service
Respiratory Tract Infections · Gastrointestinal Diseases · Asthma Exacerbations
Primary: Number of Sick Days — p=< 0.05
Phase 3 N=115 Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
Suspected or Documented Gram-negative Bacterial Infection
Primary: Percentage of Participants With One or More Adverse Event (AE) — 60.0; 50.0; 64.5; 36.4 Percentage of Participants
N/A N=110 Restricted Reporting for Positive Urine Cultures
Bacteriuria · Urinary Tract Infection
Primary: The Number of Patients Receiving Appropriate Treatment — 44; 29 Participants
Phase 3 N=725 Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
Phase 2 N=30 Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
Cystic Fibrosis · Bronchiectasis Adult · Non-Tuberculous Mycobacteria
Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate
Phase 3 N=16 The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial
Gram-Negative Bacterial Infections · Sepsis
Primary: Number of Participants Not Requiring Renal Replacement Therapy (RRT) — 3; 1 participants
Phase 4 N=162 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Bacterial Conjunctivitis
Primary: Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation — 0; 0; 0; 0 Percent of resistant isolates
N/A N=2,032 Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
Respiratory Tract Infections · Urinary Tract Infections
Primary: Number of Participants With Adverse Events — 10; 4; 6; 10 Participants — p=0.05
N/A N=120 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Community Acquired Pneumonia
Pneumonia
Primary: Use of Antibiotics in Each Group — 28; 52 participants
N/A N=54 Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial
Bacterial Vaginosis
Primary: Recurrent Bacterial Vaginosis — 7; 7 Participants — p=0.75
Phase 3 N=464 Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
Pneumonia · Blood Stream Infection
Primary: Mortality — 92; 78; 122; 133 Participants — p=0.21
N/A N=203 Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
Complicated Intra-Abdominal Infection
Primary: Duration of Hospitalization — 14.1 Days
Phase 4 N=60 Management of Sub-Clinical Bacteriuria in Pregnancy
Cystitis · Cystitis;Puerperium · Pyelonephritis
Primary: Number of Participants Who Have Cystitis — 4; 4 Participants
N/A N=150 Bacterial Translocation Markers as Predictors of Infectious and Inflammatory Complications in Acute Bowel Obstruction
Intestinal Obstruction · Colorectal Cancer · Post-Op Complication
Primary: Change in Number of Participants With Post-operative Infectious and Inflammatory Complications — 43; 47; 25; 17 Participants
Phase 2 N=204 Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
Complicated Intra-abdominal Infections
Primary: Number of Participants With Clinical Response at the Test of Cure (TOC) Visit — 62; 71 participants